AIP
NAGE

Ahrens Investment Partners’s Niagen Bioscience NAGE Stock Holding History

Ahrens Investment Partners’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-11,000
Closed -$53K – 235
2020
Q4 		$53K Buy
+11,000
New +$53.6K 0.03% 185

Other funds holding NAGE

YRHAM
Yong Rong (HK) Asset Management Sheung Wan, Hong Kong $227M AUM 300.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Ahrens Investment Partners's NAGE Position: Q1 2021 in Review

Ahrens Investment Partners sold out of Niagen Bioscience (NAGE) in Q1 2021, closing a stake of 11,000 shares — an estimated $53K sold.

Ahrens Investment Partners first reported a position in NAGE in Q4 2020 and held it in 1 quarter. The position peaked at $53K in Q4 2020. 96 funds tracked by Wall St. Rank hold NAGE as of Q1 2021.

  • Ahrens Investment Partners reported no remaining Niagen Bioscience position as of Q1 2021 after selling out during the quarter.
  • Ahrens Investment Partners sold 11,000 Niagen Bioscience shares in Q1 2021, an estimated $53K.
  • Ahrens Investment Partners first reported a position in Niagen Bioscience in Q4 2020 and held it in 1 quarter.
  • Ahrens Investment Partners's Niagen Bioscience position peaked at $53K in Q4 2020.
  • 96 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2021.

Based on Ahrens Investment Partners's 13F filing for Q1 2021, filed 5 May 2021.